2nd Quarter - Report

BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY

Firm
Client
Income
—
Expenses
$809,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Welfare WEL

NO BILL, WIC Program. Lobbied on reauthorization of WIC Program.

LobbyistCovered position, as disclosed
MICHAEL CAROZZA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

NO BILL, Tax Reform. Lobbied to gather information on potential legislation regarding deferral of foreign income.

LobbyistCovered position, as disclosed
MICHAEL CAROZZA —
CHRISTOPHER PERNIE —
RICHARD THOMPSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.

LobbyistCovered position, as disclosed
LANE PENRY —
CHRISTOPHER PERNIE —
RICHARD THOMPSON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1706 (111th), H.R. 1260 (111th), S. 515 (111th), S. 369 (111th)

Health Issues HCR

NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1548, Pathway for Biosimilars Act. Lobbied Members of congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R.1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs. HELP Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Comprehensive Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs.

LobbyistCovered position, as disclosed
MICHAEL CAROZZA —
LANE PENRY —
CHRISTOPHER PERNIE —
SHAWN ZEDDIE TARRANT New —
RICHARD THOMPSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2502 (111th), S. 525 (111th), H.R. 1427 (111th), H.R. 1298 (111th), H.R. 1105 (111th), S. 726 (111th), S. 1232 (111th), H.R. 1548 (111th), S. 1213 (111th), S. 982 (111th), H.R. 759 (111th), H.R. 1 (111th)

Medicare/Medicaid MMM

NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied members of Congress in support of early treatment of HIV/AIDS. H.R. 684 and S. 330, Medicare Prescription Drug Savings and Choice Act. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574 and S. 254, Medicare Home Infusion Therapy Coverage Act.Lobbied for passage of the bill. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. S. 547, Drug Rebate Equalization Act. Lobbied against extending the Medicaid rebate to managed care organizations.

LobbyistCovered position, as disclosed
MICHAEL CAROZZA —
LANE PENRY —
CHRISTOPHER PERNIE —
SHAWN ZEDDIE TARRANT New —
RICHARD THOMPSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 547 (111th), H.R. 1458 (111th), S. 301 (111th), H.R. 574 (111th), S. 565 (111th), S. 254 (111th), S. 330 (111th), H.R. 1616 (111th), H.R. 684 (111th)

Budget/Appropriations BUD

H.Con.Res 85, S.Con.Res 13, House and Senate Budget Resolutions. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.Con.Res 85, Function 150, House and Senate Budget Resolutions. Lobbied Members of Congress to keep the current International Affairs FY2010 Budget.

LobbyistCovered position, as disclosed
MICHAEL CAROZZA —
LANE PENRY —
CHRISTOPHER PERNIE —
DAVID E WARR —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.Con.Res. 85 (111th), S.Con.Res. 13 (111th)

Consumer Issues/Safety/Products CSP

NO BILL, Bisphenol A (BPA). Lobbied Members of Congress regarding BPA in containers.

LobbyistCovered position, as disclosed
MICHAEL CAROZZA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.